Healthcare provider profile · identity verified

Hau Do, MD

Family Practice · COSTA MESA, CA · NPI 1508209164

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	609	221
Losartan Potassium	Losartan Potassium	227	83
Levothyroxine Sodium	Levothyroxine Sodium	209	58
Amlodipine Besylate	Amlodipine Besylate	191	69
Lisinopril	Lisinopril	186	65
Trazodone Hcl	Trazodone Hcl	148	45
Rosuvastatin Calcium	Rosuvastatin Calcium	146	52
Metformin Hcl Er	Metformin Hcl	133	50
Meloxicam	Meloxicam	132	56
Omeprazole	Omeprazole	127	50
Metformin Hcl	Metformin Hcl	110	35
Terazosin Hcl	Terazosin Hcl	101	40
Glipizide	Glipizide	94	36
Gabapentin	Gabapentin	91	35
Atenolol	Atenolol	84	29
Metoprolol Tartrate	Metoprolol Tartrate	79	35
Albuterol Sulfate Hfa	Albuterol Sulfate	76	54
Pradaxa	Dabigatran Etexilate Mesylate	75	25
Hydrochlorothiazide	Hydrochlorothiazide	73	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	66	26
Finasteride	Finasteride	58	21
Tamsulosin Hcl	Tamsulosin Hcl	58	20
Alendronate Sodium	Alendronate Sodium	56	22
Azithromycin	Azithromycin	56	52
Allopurinol	Allopurinol	55	19
Bisoprolol Fumarate	Bisoprolol Fumarate	55	21
Wixela Inhub	Fluticasone Propion/Salmeterol	53	28
Furosemide	Furosemide	50	22
Simvastatin	Simvastatin	50	17
Jardiance	Empagliflozin	49	18
Ibuprofen	Ibuprofen	47	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	suppressed
Metoprolol Succinate	Metoprolol Succinate	39	14
Potassium Chloride	Potassium Chloride	38	15
Ezetimibe	Ezetimibe	35	11
Sertraline Hcl	Sertraline Hcl	33	12
Triamcinolone Acetonide	Triamcinolone Acetonide	33	24
Eliquis	Apixaban	32	suppressed
Ozempic	Semaglutide	31	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	29	12
Humulin N Kwikpen	Insulin Nph Human Isophane	26	suppressed
Cephalexin	Cephalexin	25	23
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Lovastatin	Lovastatin	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	14
Donepezil Hcl	Donepezil Hcl	24	11
Doxycycline Monohydrate	Doxycycline Monohydrate	24	19
Duloxetine Hcl	Duloxetine Hcl	24	12
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Prednisone	Prednisone	23	23
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	22	22
Fenofibrate	Fenofibrate	22	suppressed
Carvedilol	Carvedilol	21	suppressed
Ciclopirox	Ciclopirox	21	11
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	20	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	17
Gavilyte-C	Peg3350/Sod Sulf,bicarb,cl/Kcl	20	20
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Liraglutide	Liraglutide	20	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	20	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Topiramate	Topiramate	17	suppressed
Acyclovir	Acyclovir	15	suppressed
Naltrexone Hcl	Naltrexone Hcl	15	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Famotidine	Famotidine	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error